 Treatment Strategy for Benign Prostatic Hyperplasia In 2024 | |
| 主辦單位 | 社團法人高雄縣醫師公會 |
| 協辦單位 | 高雄市立鳳山醫院（委託長庚醫療財團法人經營） |
| 上課日期時間 | 113年5月15日（三）12:30-14:30 |
| 上課地點 | 高雄市立鳳山醫院（委託長庚醫療財團法人經營）八樓會議室（高雄市鳳山區經武路42號） |
| 報名截止日期 | 報名至即日起至113年5月8日下午四時止 |
| 講師 | 莊燿吉／長庚醫療財團法人高雄長庚紀念醫院泌尿科 |
| 申請積分 | 中華民國醫師公會全國聯合會、家醫科 |
| 課程簡介 | Benign prostatic hyperplasia (BPH), a nonmalignant enlargement of the prostate, is one of the most common conditions affecting aging men. It has been hypothesized that pathways involving androgens, estrogens, insulin, inflammation, proliferative reawakening, stem cells and telomerase are all contributed to the pathogenesis of the disease. The fundamental aspects of the disease include interaction between the prostatic hyperplasia, bladder outlet obstruction, and lower urinary tract symptoms (LUTS). The LUTS associated with BPH can be categorized into voiding symptoms and storage symptoms. The degree to which the symptoms bother the patient and impair quality of life is the key factor for seeking treatment from a urologist. Medical therapies widely used today for treating BPH are targeted at relaxing prostate smooth muscle tone, such as -blockers, or at reducing prostate volume, such as 5- reductase inhibitors. Transurethral resection of the prostate (TURP) has been a gold standard for surgical treatment of BPH. Nevertheless, there have been concerns about the safety of TURP, with associated morbidity including bleeding, retrograde ejaculation, bladder neck contracture, and impotence. Consequently, there have been many innovations in the development of minimally invasive therapies for BPH. The field continues to evolve with the introduction of new energy and laser technologies. In conclusion, the treatment of BPH should focus on the patient’s need, doctors’ preference, and institutional facility and intend to achieve a satisfactory outcome. |